^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SAA1 (Serum Amyloid A1)

    i
    Other names: SAA1, Serum Amyloid A1, Tumor Protein P53 Inducible Protein 4, TP53I4
    10d
    Interpreting the Theranostic Applications of Alumina and Silica Substrates in Cancer. (PubMed, Molecules)
    Furthermore, we highlight the development of highly promising alumina- and silica-based platforms for drug delivery (e.g., chemotherapeutics, photosensitizers, or gene delivery agents) in cancer. Ultimately, by providing a comprehensive overview alongside a critical analysis, we demonstrate that such nanostructures represent promising platforms for potential clinical translation in cancer medicine, helping to mitigate the limitations of conventional cancer therapies.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MUC1 (Mucin 1) • SAA1 (Serum Amyloid A1) • EPCAM (Epithelial cell adhesion molecule)
    1m
    Integrative Transcriptomic and Perturbagen Analyses Reveal Sex-Specific Molecular Signatures Across Glioma Subtypes. (PubMed, Cancers (Basel))
    Perturbagen analysis nominated signature-reversing compounds across sexes, including histone deacetylase inhibitors, Aurora kinase inhibitors, microtubule-targeting agents such as vindesine, and multi-kinase inhibitors targeting VEGFR, PDGFR, FLT3, PI3K, and MTOR. Glioma grade comparisons reveal a shared neuronal-synaptic program accompanied by sex-specific transcriptional remodeling. These findings support sex-aware therapeutic strategies that pair modulation of neuron-glioma coupling with chromatin- or receptor tyrosine kinase/angiogenic-targeted agents, and they nominate biomarkers such as GLI1, MYOD1, GCGR, PRLHR, and HIST1H2BH for near-term validation.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • GLI1 (GLI Family Zinc Finger 1) • SAA1 (Serum Amyloid A1) • HOXA9 (Homeobox A9) • GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A) • CHRNA7 (Cholinergic Receptor Nicotinic Alpha 7 Subunit) • GRIN2B (Glutamate Ionotropic Receptor NMDA Type Subunit 2B) • MYOD1 (Myogenic Differentiation 1)
    |
    vindesine
    2ms
    Targeting PAK1 suppresses tumor progression by promoting mRNA decay of oncogenic factors and enhancing chemotherapeutic efficacy in colorectal cancer. (PubMed, Genes Dis)
    Importantly, our results revealed that the PAK1 inhibitor, PF3758309, exhibited a profound synergistic effect with oxaliplatin in CRC. Collectively, our study unveils a novel function of PAK1 in CRC progression. Thus, these results highlight the potential of targeting PAK1 as a therapeutic strategy in CRC, particularly in combination with oxaliplatin.
    Journal
    |
    CD44 (CD44 Molecule) • SAA1 (Serum Amyloid A1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • PAK1 (p21 (RAC1) activated kinase 1) • EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1)
    |
    oxaliplatin • PF-3758309
    2ms
    Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC - Insights From Genomics, Proteomics, and Metabolomics. (PubMed, Lung Cancer (Auckl))
    Although promising, most biomarkers require prospective validation in large, uniformly treated cohorts. Integrative strategies-particularly when combined with AI-driven analytics-hold potential to refine patient stratification and guide clinical use of ICIs in NSCLC.
    Review • Journal • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metabolomic study
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • FASLG (Fas ligand) • S100A8 (S100 Calcium Binding Protein A8) • SAA1 (Serum Amyloid A1) • CASP8 (Caspase 8)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • BRAF V600 • RET fusion • STK11 mutation • TMB-L • KEAP1 mutation • ROS1 fusion
    2ms
    Stromal fibroblastic mutant Trp53 promotes mammary tumor development via enhanced secretion of paracrine factors. (PubMed, NPJ Breast Cancer)
    Consistently, supplementing primary HER2-positive tumor cultures with recombinant SAA1, SAA2, or THBS4 peptides enhanced tumor cell proliferation and migration. Together, these findings uncover a mechanism by which fibroblastic mutant p53 promotes mammary tumorigenesis-through upregulating secretory proteins such as SAA1, SAA2, and THBS4 in the stroma, thereby enhancing PI3K/AKT signaling and tumor progression.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • SAA1 (Serum Amyloid A1) • SAA2 (Serum Amyloid A2)
    |
    HER-2 positive • TP53 mutation • TP53 wild-type
    3ms
    Construction and validation of an oxidative phosphorylation-related gene signature in lung squamous cell carcinoma patients. (PubMed, Lung Cancer Manag)
    This signature highlights the clinical relevance of OXPHOS in LUSC prognosis and may guide personalized therapeutic strategies targeting metabolic vulnerabilities. Study limitations include its retrospective design and lack of experimental validation.
    Journal • Gene Signature
    |
    SAA1 (Serum Amyloid A1) • LTBP1 (Latent-transforming growth factor beta-binding protein 1) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CDC25C (Cell Division Cycle 25C) • SAAL1 (Serum Amyloid A Like 1) • CD59 (CD59 Molecule) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
    3ms
    Exploration of oxidative stress-related molecular signature for clear cell renal cell carcinoma. (PubMed, Discov Oncol)
    In conclusion, we conducted a thorough analysis of the expression profiles of OSRGs in ccRCC, culminating in the development of a robust prognostic model and scoring system aimed at accurately predicting survival outcomes for ccRCC patients. This endeavor has the potential to yield novel insights into redox biology and to advance the current treatment strategies for ccRCC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD276 (CD276 Molecule) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • MAGEA4 (Melanoma antigen family A, 4) • SAA1 (Serum Amyloid A1) • CDCA3 (Cell Division Cycle Associated 3) • IRF6 (Interferon Regulatory Factor 6)
    3ms
    SAA1 Induces TGF-β1 Secretion by Ovarian Cancer Cells, Leading to M2 Macrophage Polarization and Inhibition of NK Cell Activity. (PubMed, FASEB J)
    SAA1 repressed NK cell killing in ovarian cancer by facilitating M2 macrophage polarization through TGF-β1. The findings suggested that SAA1 may be a target for ovarian cancer therapy.
    Journal
    |
    SAA1 (Serum Amyloid A1) • TGFB1 (Transforming Growth Factor Beta 1)
    3ms
    TGFβ signaling in cancer-associated fibroblasts drives a hepatic gp130-dependent pro-metastatic inflammatory program in colorectal cancer. (PubMed, iScience)
    This IL-6 family-JAK/STAT stromal signaling axis is active in both a murine model of CMS4 as well as in patients with human CRC in vivo. Combined, our data reveal that TGFβ-driven CAF signaling actively contributes to the formation of a neutrophil-dependent, pre-metastatic hepatic niche in the metastatic phenotype of CMS4 CRC.
    Journal
    |
    IL6 (Interleukin 6) • SAA1 (Serum Amyloid A1)
    5ms
    Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1-IL-1β axis. (PubMed, J Exp Clin Cancer Res)
    This study uncovers a novel SAA1-IL-1β feedback loop that promotes immunosuppression and progression in ovarian cancer. These findings provide insight into tumor-immune interactions and suggest a potential biomarker and therapeutic target for EOC.
    Journal • IO biomarker
    |
    CD33 (CD33 Molecule) • SAA1 (Serum Amyloid A1) • IL1B (Interleukin 1, beta) • TLR2 (Toll Like Receptor 2)
    5ms
    CLDN4 regulates cell proliferation in small cell lung cancer cells via SAA1 inhibition. (PubMed, Biochem Biophys Res Commun)
    However, its treatment still relies on a combination of platinum-based chemotherapy and etoposide, and a new effective therapeutic strategy is urgently needed...CLDN4 expression was directly regulated by SP1, with DNA methylation also contributing to its transcriptional regulation. These findings indicate that CLDN4, which is transcriptionally regulated by SP1 and DNA methylation, suppresses SCLC cell proliferation by inhibiting SAA1 expression and may serve as a potential therapeutic target.
    Journal
    |
    SAA1 (Serum Amyloid A1)
    |
    etoposide IV
    5ms
    Differentiating Gastric Cancers from Acid Peptic Diseases through Integrative Targeted Proteomics and Machine Learning Approaches. (PubMed, J Proteome Res)
    Importantly, the DNN-based scoring architecture efficiently differentiated GCs from the rest of the samples (AUROC = 0.95), with average precision marking >0.90 and minimal bias in protein expression affecting model performance. This LDT can serve as a prediagnostic screening method to distinguish GCs from APDs, guiding clinicians and patients in proceeding with a confirmatory diagnosis.
    Journal
    |
    SAA1 (Serum Amyloid A1) • IGFBP2 (Insulin-like growth factor binding protein 2)